What if the tumor inside you could simply pretend to be dead while chemotherapy raged through your body, then yawn, stretch, and start growing again the moment the drugs cleared out? Not because it mutated into some indestructible supervillain, but because it pulled the biological equivalent of hiding under the bed until mom stopped looking?
That sounds like the plot of a bad horror movie sequel. But it's real - and it's one of the most important discoveries in breast cancer research over the past decade, courtesy of a scientist named Helen Piwnica-Worms.
The Woman Who Caught Cancer Faking It
A recent PNAS profile chronicles the career of Piwnica-Worms, who has spent decades figuring out how cancer cells dodge the bullets we fire at them. She started by mapping the molecular switches that control when cells divide - the so-called cell cycle checkpoints. Her early work identified how a protein called Wee1 slams the brakes on cell division and how checkpoint kinase 1 (CHK1) acts as the security guard that stops damaged cells from multiplying.
That's all very textbook-cool, but here's where it gets personal for anyone who's sat in an infusion chair: she took that basic science knowledge and aimed it squarely at the problem of why treatments stop working.
Playing Possum at the Molecular Level
In 2019, Piwnica-Worms and her team at MD Anderson Cancer Center published a finding that genuinely changed how oncologists think about treatment failure. Using patient-derived tumor models from a clinical trial, they showed that triple-negative breast cancer cells don't always resist chemotherapy by developing permanent genetic armor. Instead, some tumors enter a reversible "drug-tolerant persister" state - they temporarily flip on protective pathways, ride out the chemo storm, and then flip those pathways back off when treatment ends.
The tumors literally became sensitive to the same chemotherapy again once it was paused. For someone sitting in that infusion chair wondering why their scan went from "responding" to "progressing," this distinction matters enormously. It means the enemy isn't necessarily evolving - it's adapting. And adaptations, unlike mutations, might be something we can outsmart.
The team also found that these sneaky persister cells ramp up their energy production through oxidative phosphorylation - basically switching to a backup generator. Target that generator, and you might catch the cancer while it's still hiding under the bed.
Two Escape Routes, One Very Determined Tumor
Piwnica-Worms' latest work, published as her PNAS Inaugural Article in 2026, tackles another layer of resistance - this time in BRCA1-mutant breast cancers treated with talazoparib, a PARP inhibitor. PARP inhibitors were supposed to be the targeted therapy ace for patients carrying BRCA mutations. And they work, until they don't.
Her team discovered that tumors escaping talazoparib aren't using just one exit door. They've got two: one driven by a transcription factor called BRN2 that cranks up ATR/STAT3 signaling pathways, and another involving expansion of cancer cell subclones that have lost a protein called SHLD2 (part of the Shieldin complex that normally helps repair DNA breaks).
Two different escape routes in the same disease. For patients, this means a single combination therapy might not block both exits. But knowing the exits exist? That's the first step toward stationing guards at each one.
Why This Matters Beyond the Lab Bench
Her team also showed that cell cycle plasticity - basically cancer cells finding alternate paths through the division cycle - drives resistance to CDK4/6 inhibitors like palbociclib in ER-positive breast cancer. Individual cells rewire their internal clocks to bypass the drug, not through mutations but through good old-fashioned biological improvisation.
The throughline across all of Piwnica-Worms' work is both sobering and hopeful: cancer is more flexible than we thought, but flexibility has rules. Reversible resistance means the window for treatment isn't always slammed shut - sometimes it's just stuck. Patient-derived models that mirror real human tumors, rather than lab-grown cell lines that have been dividing since before the internet existed, make it possible to study these real-world escape tactics.
For anyone in treatment, the message here isn't "resistance is inevitable." It's "resistance is understandable." And what we can understand, we can eventually outmaneuver.
References
-
Williams SCP. Profile of Helen M. Piwnica-Worms. Proc Natl Acad Sci U S A. 2026;123(16). DOI: 10.1073/pnas.2609807123. PMID: 41973922
-
Echeverria GV, Ge Z, Seth S, et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci Transl Med. 2019;11(488):eaav0936. DOI: 10.1126/scitranslmed.aav0936. PMID: 30996079
-
Yang C, Fujiwara Y, Bhatt DK, et al. Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cells. Proc Natl Acad Sci U S A. 2024;121(8):e2309261121. DOI: 10.1073/pnas.2309261121. PMID: 38324568
-
Shen S, Vagner S, Robert C. Persistent cancer cells: the deadly survivors. Cell. 2020;183(4):860-874. DOI: 10.1016/j.cell.2020.10.027
-
Shao F, Bhatt DK, et al. PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge. Exp Mol Med. 2026. DOI: 10.1038/s12276-026-01673-8
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.